NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: HXNet

Published 12 Nov 2026. 41-page investigative report on who is behind HXNet: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 175 Finnrick lab tests, HXNet records 143 pass / 29 fail, an 82% overall pass rate. That headline hides a split catalog: Tirzepatide, GHK-Cu and Retatrutide are the strongest supported lines, while TB-500 is the clearest weak blind-buy candidate. Ratings also compress under stricter grading, so the public score is a screen, not a batch certificate.

The bigger issue is the counterparty and paper trail. Chinese registry snippets and a Wayback-preserved ChemicalBook profile tie the brand to a Shijiazhuang anchor entity shown as deregistered before the visible 2025–2026 sales run; the current accountable company is not established in the reviewed public record.

The polished hxnetpeptides.com property is more problematic than reassuring. Its 44-file COA library is self-verified, batch-generated and includes certificates whose report suffixes, access codes and purity results align with Peptide Partners/Kovera records. Separately, the public seller announced an October split from HXTNT into LaraPharma channels, while Telegram authentication and official-domain control remain unresolved.

Batch evidence reinforces that HXNet is a channel-and-lot decision, not a brand-level trust decision. The report documents an acknowledged HCG endotoxin refund event and a PT-141 adverse-reaction complaint with a vendor testing offer; neither erases the stronger GLP-1 lines, but both make identity, fill, purity and endotoxin evidence essential for the exact lot.

Inside the full report:

  • Per-product pass/fail rates and methodology-divergence charts for all 12 tested products
  • Chinese registry snippets, Wayback ChemicalBook capture and entity-lifecycle timeline
  • Side-by-side COA comparisons showing copied Kovera suffixes, access codes and results
  • RDAP and domain review of hxnetpeptides.com, hxnet.net, hbxunou.com, hxtnt.com and LaraPharma infrastructure
  • Forum and pastebin evidence for the HXTNT split, LaraPharma rebrand, HCG endotoxin event and PT-141 complaint
  • Buyer verification checklist for legal entity, official channel, independent COA and endotoxin proof

Risk assessment

  • COA and documentation-integrity risk — high: hxnetpeptides.com published 44 self-generated COAs; Klow KW202604 and Tirzepatide TZ202605 copy Peptide Partners/Kovera identifiers and results.
  • Corporate identity and accountability risk — high: The documented Hebei Xun'ou entity was deregistered on 2025-04-10, while the current HXNet/HXTNT/LaraPharma legal entity and operator ownership remain unresolved.
  • Product-quality risk for weak lines and incident batches — high: TB-500, Sermorelin, CJC-1295 and Tesamorelin have weak Finnrick ratings; HCG 5k endotoxin and PT-141 adverse-event reports show batch-level release failures.
  • Brand-confusion and impersonation risk — high: No canonical official domain or authenticated channel list exists; hxnetpeptides.com may be official or brand-jacking, @LaraPharma is unverified, and search results include spam pages.
  • Prescription-product gray-market risk — medium: The US paste lists NovoLog, Humalog, Lantus, Fiasp, Tresiba, Lyumjev and Dexcom G7 without visible lot, authorization or cold-chain documentation.